CC-99677 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 271 | 強直性脊椎炎 | 4 |
271. 強直性脊椎炎
臨床試験数 : 574 / 薬物数 : 359 - (DrugBank : 68) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-004108-37-CZ (EUCTR) | 14/10/2021 | 09/03/2021 | A study to determine how effective and safe the drug CC-99677 is for patients with active Ankylosing Spondylitis | A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects with Active Ankylosing Spondylitis | Ankylosing Spondylitis MedDRA version: 20.0;Level: PT;Classification code 10002556;Term: Ankylosing spondylitis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Code: CC-99677 60mg Capsule INN or Proposed INN: 146368 Other descriptive name: CC-99677 Product Code: CC-99677 30mg Capsule INN or Proposed INN: 146368 Other descriptive name: CC-99677 | Celgene Corporation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 256 | Phase 2 | United States;Czechia;Czech Republic;Canada;Spain;Poland;Turkey;Romania;Russian Federation;Germany | ||
| 2 | EUCTR2019-004108-37-PL (EUCTR) | 13/09/2021 | 01/04/2021 | A study to determine how effective and safe the drug CC-99677 is for patients with active Ankylosing Spondylitis | A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects with Active Ankylosing Spondylitis | Ankylosing Spondylitis MedDRA version: 20.0;Level: PT;Classification code 10002556;Term: Ankylosing spondylitis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Code: CC-99677 60mg Capsule INN or Proposed INN: 146368 Other descriptive name: CC-99677 Product Code: CC-99677 30mg Capsule INN or Proposed INN: 146368 Other descriptive name: CC-99677 | Celgene Corporation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 256 | Phase 2 | United States;Czechia;Czech Republic;Canada;Spain;Poland;Turkey;Romania;Russian Federation;Germany | ||
| 3 | NCT04947579 (ClinicalTrials.gov) | August 25, 2021 | 23/6/2021 | A Study of CC-99677 in Participants With Active Ankylosing Spondylitis | A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects With Active Ankylosing Spondylitis | Spondylitis, Ankylosing | Drug: CC-99677;Other: Placebo | Celgene | NULL | Terminated | 18 Years | 65 Years | All | 167 | Phase 2 | United States;China;Czechia;Germany;Poland;Romania;Spain;Turkey;Canada;Russian Federation |
| 4 | EUCTR2019-004108-37-DE (EUCTR) | 09/07/2021 | 18/02/2021 | A study to determine how effective and safe the drug CC-99677 is for patients with active Ankylosing Spondylitis | A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects with Active Ankylosing Spondylitis | Ankylosing Spondylitis MedDRA version: 20.0;Level: PT;Classification code 10002556;Term: Ankylosing spondylitis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Code: CC-99677 60mg Capsule INN or Proposed INN: 146368 Other descriptive name: CC-99677 Product Code: CC-99677 30mg Capsule INN or Proposed INN: 146368 Other descriptive name: CC-99677 | Celgene Corporation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 256 | Phase 2 | United States;Czechia;Czech Republic;Canada;Spain;Poland;Turkey;Romania;Russian Federation;Germany |